Vericel Corporation presented an update highlighting its position as a leading provider of advanced therapies in sports medicine and severe burn care. The company reported a high revenue growth profile, sustained positive adjusted EBITDA, and operating cash flow, supported by approximately $200 million in cash and investments. Vericel’s sports medicine franchise, led by its knee cartilage repair products, was noted as a market leader, with the company targeting a U.S. addressable market of $4 billion. The presentation outlined mid-term targets, including a goal of doubling revenue by 2029 to nearly $500 million, maintaining a gross margin in the high 70% range, and expanding its adjusted EBITDA margin into the high 30% range. Growth initiatives include the launch of new products, expansion of the sales force, new clinical studies, and increased manufacturing capacity for potential international expansion. Vericel also reported progress in its severe burn care portfolio, with recent product launches and expanded indications. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vericel Corporation published the original content used to generate this news brief on January 12, 2026, and is solely responsible for the information contained therein.